BiotechTube
Home/Pipeline/ApDC Oncology Platform

ApDC Oncology Platform

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication
Oncology (unspecified)
Phase
Pre-clinical
Status
Active
Company
Guardian Therapeutics

About Guardian Therapeutics

Guardian Therapeutics is a private, pre-revenue biotech pioneering the development of aptamer drug conjugates (ApDCs) and other aptamer therapeutics. The company's platform enables rapid discovery of therapeutic aptamers with high affinity and stability, targeting a broad pipeline across hematology, gastroenterology, dermatology, and oncology. Led by co-founders CEO Jim Gilbert, MD, and CSO Shuhao Zhu, PhD, the company is advancing its platform and pipeline from its headquarters in Lowell, Massachusetts. Guardian's strategy positions it to capitalize on the potential advantages of aptamers over traditional antibody-based therapies.

View full company profile

Therapeutic Areas

HematologyGastroenterologyDermatologyOncologyImmunology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a